Sign Up to like & get
recommendations!
0
Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000849
Abstract: Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies between assays for the various sorts of FVIII molecules. The advent of novel nonfactor therapies (emicizumab, fitusiran, and anti-tissue factor pathway inhibitor antibodies) in…
read more here.
Keywords:
treatments new;
hemophilia treatments;
monitoring hemophilia;
laboratory monitoring ... See more keywords